Statistical methods in oncology trials
The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.
Hazard ratio
Log-rank test
Cochran-Mantel-Haenszel test
Odds ratio
Cox proportional-hazards model
Fisher exact test
Risk difference
Stratified log-rank test
All oncology trials
2,067 results
- High-dose Bevacizumab in Advanced Renal Carcinoma Patients: Complete Statistical AnalysisIndependent statistical analysis of High-dose Bevacizumab in Advanced Renal Carcinoma Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00455975).
- High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for t-MDS/t-AML: Complete Statistical AnalysisIndependent statistical analysis of High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for t-MDS/t-AML: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00774046).
- High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00349778).
- High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy: Complete Statistical AnalysisIndependent statistical analysis of Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03388619).
- HIMALAYAComplete statistical analysis of the phase 3 HIMALAYA trial of durvalumab and tremelimumab in advanced hepatocellular carcinoma, including trial design, overall survival, non-inferiority methodology, Cox regression, log-rank testing, and interpretation.
- HIPPOIndependent statistical analysis of Helping Improve Pediatric Patient Outcomes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03471221).
- Histologic Assessment of the Difference Between 18F-2-fluoro-2-deoxy_D-glucose Positron Emission Mammography(PEM) and Magnetic Resonance Imaging (MRI) of the Breast: Complete Statistical AnalysisIndependent statistical analysis of Histologic Assessment of the Difference Between 18F-2-fluoro-2-deoxy_D-glucose Positron Emission Mammography(PEM) and Magnetic Resonance Imaging (MRI) of the Breast: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- HM2014-26 DT2219 for Relapsed or Refractory B-Lineage Leukemia or Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of HM2014-26 DT2219 for Relapsed or Refractory B-Lineage Leukemia or Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02370160).
- HNC-RCIndependent statistical analysis of Development and Evaluation of Rehabilitation Consult for Survivors of Head and Neck Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Home Based Daratumumab Administration for Patients With Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Home Based Daratumumab Administration for Patients With Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05511428).
- HORIZON IIIndependent statistical analysis of Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- HPV Vaccine Intervention for Young Sexual Minority Men: Complete Statistical AnalysisIndependent statistical analysis of HPV Vaccine Intervention for Young Sexual Minority Men: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04032106).
- Human Immune Globulin in Treating Patients With Primary Amyloidosis That is Causing Heart Dysfunction: Complete Statistical AnalysisIndependent statistical analysis of Human Immune Globulin in Treating Patients With Primary Amyloidosis That is Causing Heart Dysfunction: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Hydroxychloroquine to Increase Tumor Suppressor PAR-4 Levels in Oligometastatic Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Hydroxychloroquine to Increase Tumor Suppressor PAR-4 Levels in Oligometastatic Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Hydroxychloroquine, Carboplatin, Paclitaxel, and Bevacizumab in Recurrent Advanced Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Hydroxychloroquine, Carboplatin, Paclitaxel, and Bevacizumab in Recurrent Advanced Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Hypofractionated IMRT With Temozolomide for HGG: Complete Statistical AnalysisIndependent statistical analysis of Hypofractionated IMRT With Temozolomide for HGG: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02082119).
- Hypofractionated Pre-operative Radiation Therapy for Soft Tissue Sarcomas of the Extremity and Chest-wall: Complete Statistical AnalysisIndependent statistical analysis of Hypofractionated Pre-operative Radiation Therapy for Soft Tissue Sarcomas of the Extremity and Chest-wall: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Hypofractionated Radiation Therapy or Standard Radiation Therapy in Treating Patients With Ductal Breast Carcinoma In Situ or Early Invasive Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Hypofractionated Radiation Therapy or Standard Radiation Therapy in Treating Patients With Ductal Breast Carcinoma In Situ or Early Invasive Breast Cancer: primary endpoint results, effect estimate with confidence…
- I-SCREENIndependent statistical analysis of Increasing Screening for Cancer Using EHR-Nudges: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06177795).
- I-SPY 1A detailed statistical analysis of I-SPY 1, a phase 2 single-group diagnostic study evaluating MRI/MRS in women receiving chemotherapy for stage III breast cancer, with disease-free three-year survival as the registered primary…
- IALTAn independent statistical analysis of IALT (NCT00002823), a randomized phase 3 trial comparing combination chemotherapy with no treatment following surgery in patients with lung cancer.
- IBCSG 23-01Independent statistical analysis of IBCSG 23-01, a randomized trial of axillary lymph node dissection versus no axillary lymph node dissection in women with node-negative breast cancer and sentinel lymph node micrometastases.
- Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.: Complete Statistical AnalysisIndependent statistical analysis of Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant: Complete Statistical AnalysisIndependent statistical analysis of Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- ICON6A detailed statistical analysis of the ICON6 phase 3 randomized trial of concurrent and maintenance cediranib in women with platinum-sensitive relapsed ovarian cancer, including its design, progression-free survival endpoint, planned statistical analysis,…
- ICON7Independent statistical analysis of ICON7 (NCT00483782), a randomized phase 3 trial evaluating carboplatin and paclitaxel with or without bevacizumab in newly diagnosed ovarian epithelial, fallopian tube, or primary peritoneal cavity cancer.
- ICT-HCTIndependent statistical analysis of Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Id-KLH Vaccine + T Cells in Subjects With Myeloma Undergoing Transplant: Complete Statistical AnalysisIndependent statistical analysis of Id-KLH Vaccine + T Cells in Subjects With Myeloma Undergoing Transplant: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- IFCT-0501An independent statistical analysis of IFCT-0501, a randomized phase 3 trial comparing paclitaxel plus carboplatin with monotherapy in patients with NSCLC, including the trial design, overall survival endpoint, planned analysis, and statistical…
- IKEMAIndependent statistical analysis of Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients: primary endpoint results, effect estimate with confidence interval, sample-size…
- IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT: Complete Statistical AnalysisIndependent statistical analysis of IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- IMIndependent statistical analysis of Acetic Acid Chromoendoscopy to Judge Gastric Intestinal Metaplasia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01499576).
- Image Evaluation of Philips Philips MammoDiagnost DR Full Field Digital Mammography System (FFDM): Complete Statistical AnalysisIndependent statistical analysis of Image Evaluation of Philips Philips MammoDiagnost DR Full Field Digital Mammography System (FFDM): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Image-Guided Navigation for High Dose Rate Temporary Interstitial Brachytherapy in the Palliative Management of Previously Treated Tumors of the Spine and Pelvis: Complete Statistical AnalysisIndependent statistical analysis of Image-Guided Navigation for High Dose Rate Temporary Interstitial Brachytherapy in the Palliative Management of Previously Treated Tumors of the Spine and Pelvis: primary endpoint results, effect estimate with…
- Image-Guided Radiosurgery or Stereotactic Body Radiation Therapy in Treating Patients With Localized Spine Metastasis: Complete Statistical AnalysisIndependent statistical analysis of Image-Guided Radiosurgery or Stereotactic Body Radiation Therapy in Treating Patients With Localized Spine Metastasis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Imaging in MGUS, SMM and MM: Complete Statistical AnalysisIndependent statistical analysis of Imaging in MGUS, SMM and MM: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01237054).
- Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy: Complete Statistical AnalysisIndependent statistical analysis of Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Imiquimod for Breast Cancer Patients With Chest Wall Recurrence or Skin Metastases: Complete Statistical AnalysisIndependent statistical analysis of Imiquimod for Breast Cancer Patients With Chest Wall Recurrence or Skin Metastases: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Immediate-Release Oxycodone Capsules Study in Cancer Pain: Complete Statistical AnalysisIndependent statistical analysis of Immediate-Release Oxycodone Capsules Study in Cancer Pain: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01675622).
- IMmotion151Independent statistical analysis of A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC): primary endpoint results, effect estimate with confidence interval, sample-size…
- IMMULAB – Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC): Complete Statistical AnalysisIndependent statistical analysis of IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Immune Modulation by Abemaciclib in Head and Neck Squamous Cell Carcinoma (HNSCC). (AIM Trial): Complete Statistical AnalysisIndependent statistical analysis of Immune Modulation by Abemaciclib in Head and Neck Squamous Cell Carcinoma (HNSCC). (AIM Trial): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…